erlotinib
erlotinib: 17 clinical trials tracked.
erlotinib evidence translation
What we can confirm
17 tracked trials
What it means
What to watch
Prepared research question
What is verified about erlotinib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 3 study sponsors
Clinical Trial Registry Records (17)showing 10 most recent
Study in Human iPSCs-derived Retinal Pigment Epithelium Cells Transplantation for Late-Stage Age-Related Macular Degeneration
Primary endpoint: Number of subjects with adverse events
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications
Primary endpoint: Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-355 as a single agent and in combination with each of the following agents: erlotinib, futibatinib, or BBI-825
A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
Primary endpoint: Incidence of adverse events
A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Primary endpoint: Percentage of Participants With Adverse Events (AEs)
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial
Primary endpoint: Objective response rate defined as the number of patients with complete response or partial response
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Primary endpoint: [Phase II] Progression-free Survival
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile
Primary endpoint: Percentage of patients that are treated based on their molecular tumor profile
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Primary endpoint: Part B: Progression Free Survival (PFS)
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Primary endpoint: Overall Survival (OS)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Primary endpoint: Central and local clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105